Table 4.

Prescriber versus antidepressant classes/indication/treatment duration.

		Prescriber
		General practitioner N (%)	Geriatrician N (%)	Psychiatrist N (%)	Neurologist N (%)	Unknown N (%)
AD Classes	SSRI	8 (25.8)	0 (0)	3 (50)	1 (12.5)	6 (37.5)
	TCA	9 (29)	1 (10)	1 (16.7)	1 (12.5)	3 (18.8)
	SNRI	4 (12.9)	1 (10)	0 (0)	4 (50)	2 (12.5)
	AD directly affecting NR	10 (32.3)	8 (80)	2 (33.2)	2 (25)	5 (31.3)
Indication	Depression	23 (74.2)	1 (10)	6 (100)	4 (50)	6 (37.5)
	Anxiety and panic disorder	1 (3.2)	0 (0)	0 (0)	1 (12.5)	0 (0)
	Neuropathic pain	1 (3.2)	2 (20)	0 (0)	1 (12.5)	1 (6.3)
	Behavioral disorders in dementia	1 (3.2)	3 (30)	0 (0)	1 (12.5)	1 (6.3)
	Migraine	0 (0)	0 (0)	0 (0)	1 (12.5)	0 (0)
	Sleeping disorders	3 (9.7)	4 (40)	0 (0)	0 (0)	2 (12.5)
	Others	2 (6.5)	0 (0)	0 (0)	0 (0)	0 (0)
	No indication	0 (0)	0 (0)	0 (0)	0 (0)	6 (37.5)
Treatment duration	According guideline	12 (38.7)	1 (10)	6 (100)	4 (50)	3 (18.8)
	Longer than guideline	12 (38.7)	0 (0)	0 (0)	0 (0)	0 (0)
	Unknown	0 (0)	0 (0)	0 (0)	1 (12.5)	8 (50)
	No guideline	7 (22.6)	9 (90)	0 (0)	3 (37.5)	5 (31.3)

Prescriber versus antidepressant classes: p = 0.118, Fisher Freeman Halton test; prescriber versus antidepressant indication: p < 0.001, Fisher Freeman Halton test; prescriber versus treatment duration: p < 0.001, Fisher Freeman Halton test.

AD, antidepressant; NR, neuroreceptor; SNRI, serotonin and noradrenalin reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.